# To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

> **NCT06352008** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06352008
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06352008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06352008, "To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06352008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*